Skip to content

Extracorporeal shock wave therapy (ESWT) and kinesiotherapy (KIN) on women with bilateral knee osteoarthritis

The investigation of the effects of extracorporeal shock wave therapy (ESWT) and kinesiotherapy (KIN) on health status of women with bilateral knee osteoarthritis (OA): a randomised trial

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12616000589482
Enrollment
60
Registered
2016-05-06
Start date
2015-11-02
Completion date
2016-03-21
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Despite the advances in treatment there is lack of comparative studies on the effects of ESWT and other treatments such as KIN in patients with knee OA. Objectives of Study: to compare the effects of ESWT and KIN protocol on perceived health evaluated by the Western Ontario and McMaster Universities Questionnaire (WOMAC) Osteoarthritis Index, on severity of knee pain by Visual Analogue Scale (VAS), on Range of Motion (ROM) of the knees and also on functional exercise capacity by the Six-Minute Walk Test (6-MWT) physical function, decreased exercise capacity).

Interventions

ESWT - 1,000 pulses (during the first treatment), 1,500 (during the second and the third treatment), and 2,000 (during the fourth and the fifth treatment), respectively (pressure, 2.5 bar; frequency, 8 Hz; energy density, 0.4 mJ/mm2). ESWT - 1 treatment per week. Each treatment session will not exceed 10 minutes. Intervention will be delivered by a physiotherapist KIN - 25 sessions of a physiotherapy program an hour a day, 5 days a week, for 5 weeks. Intervention will be delivered by a physiot

ESWT - 1,000 pulses (during the first treatment), 1,500 (during the second and the third treatment), and 2,000 (during the fourth and the fifth treatment), respectively (pressure, 2.5 bar; frequency, 8 Hz; energy density, 0.4 mJ/mm2). ESWT - 1 treatment per week. Each treatment session will not exceed 10 minutes. Intervention will be delivered by a physiotherapist KIN - 25 sessions of a physiotherapy program an hour a day, 5 days a week, for 5 weeks. Intervention will be delivered by a physiotherapist. The mode of delivery as face to face, The intervention will be provided individually. The Kinesiotherapy program: 1. Warm-up. 2. Stretching. 3. Strengthening. 4. Functional task-oriented training. 5. Endurance. 6. Cool down. Examples of exercises for all participants in Kin group: 1. Global flexion-extension of the lower limb. Alternated dorsal plantar flexion of the ankles. 2. Stretching of the hamstrings. 3. Isometric knee extensors: flex 0 degrees. Isometric knee extensors: flex 60 degrees. Isometric hamstrings: flex 60 degrees. Concentric-eccentric hip abductors. 4. Knee extensor strengthening while standing with Thera-Band. Controlled bilateral knee flexion-extension while standing . Climbing on a platform or a flight of stairs. Walking in place, with a large amplitude of hip and knee flexion and upper-limb movements. 5. Stationary cycling. 6. Ice for quadriceps, hamstrings, and calf. Intervention will be administered in physiotherapy department, Log of sessions attended will be maintained. Participants will never receive both intervention, two separate groups will receive only one intervention - ESWT or KIN.

Sponsors

Holycross College
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Primary purpose
Treatment

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

female gender, minimum age of 40, ability to perform physical exercises, not currently receiving any physical therapy treatments for the knee OA condition, medication compliance (all patients were taking glucocorticoids at the time of the study), and the diagnosis of bilateral knee OA according to the American College of Rheumatology criteria

Exclusion criteria

unilateral knee OA, neurological disorders, cognitive limitations or history of cardiovascular, pulmonary or endocrinology disease

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026